New Technology Bows At Seattle Genetics | September 28, 2009 Issue - Vol. 87 Issue 39 | Chemical & Engineering News
Volume 87 Issue 39 | p. 36 | Concentrates
Issue Date: September 28, 2009

New Technology Bows At Seattle Genetics

Department: Business
Keywords: Seattle Genetics, antibodies, antibody-drug conjugate

Seattle Genetics, a biotech firm known for its antibody-drug conjugate platform, has come up with a new technology that increases the potency of monoclonal antibodies. The company’s sugar-engineered antibody technology prevents fucose from being incorporated into the carbohydrate chains of monoclonal antibodies, making the drugs better at evoking an immune response. Adding these modified sugars to cell-culture media doesn’t change the antibody manufacturing process, yield, or product quality. The new technology will be incorporated into Seattle Genetics’ early-stage pipeline and could be partnered with other companies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment